Breaker peptides against amyloid-β aggregation: a potential therapeutic strategy for Alzheimer's disease.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder, for which blocking the early steps of extracellular misfolded amyloid-β (Aβ) aggregation is a promising therapeutic approach. However, the pathological features of AD progression include the accumulation of intracellular tau protein, membrane-catalyzed cell death and the abnormal deposition of Aβ. Here, we focus on anti-amyloid breaker peptides derived from the Aβ sequence and non-Aβ-based peptides containing both natural and modified amino acids. Critical aspects of the breaker peptides include N-methylation, conformational restriction through cyclization, incorporation of unnatural amino acid, fluorinated molecules, polymeric nanoparticles and PEGylation. This review confers a general idea of such breaker peptides with in vitro and in vivo studies, which may advance our understanding of AD pathology and develop an effective treatment strategy against AD.

• Publication year

  2021

• Venue

  Future Medicinal Chemistry

• Publication date

  2021-09-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.4155/fmc-2021-0184PMID 34498978
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In-situ side-chain peptide cyclization as a breaker strategy against the amyloid aggregating peptide.

  2021cited by this paper
• Structural and mechanistic insights into the inhibition of amyloid-β aggregation by Aβ39-42 fragment derived synthetic peptides.

  2020cited by this paper
• Design and synthesis of β-strand-fixed peptides inhibiting aggregation of amyloid β-protein.

  2020cited by this paper
• d-Enantiomeric RTHLVFFARK-NH2: A Potent Multifunctional Decapeptide Inhibiting Cu2+-Mediated Amyloid β-Protein Aggregation and Remodeling Cu2+-Mediated Amyloid β Aggregates.

  2019cited by this paper
• A Novel PEGylated Block Copolymer in New Age Therapeutics for Alzheimer’s Disease

  2019cited by this paper
• Carnosine-LVFFARK-NH2 Conjugate: A Moderate Chelator but Potent Inhibitor of Cu2+-Mediated Amyloid β-Protein Aggregation.

  2018cited by this paper
• RTHLVFFARK-NH2: A potent and selective modulator on Cu2+-mediated amyloid-β protein aggregation and cytotoxicity.

  2018cited by this paper
• An evaluation of memantine ER + donepezil for the treatment of Alzheimer’s disease

  2018cited by this paper
• Inhibition of β-Amyloid Aggregation through a Designed β-Hairpin Peptide.

  2018cited by this paper
• Pharmacodynamics in Alzheimer's disease model rats of a bifunctional peptide with the potential to accelerate the degradation and reduce the toxicity of amyloid β-Cu fibrils.

  2018cited by this paper
• Head-to-tail cyclization of a heptapeptide eliminates its cytotoxicity and significantly increases its inhibition effect on amyloid β-protein fibrillation and cytotoxicity

  2018cited by this paper
• β-Sheet Breaker Peptide-HPYD for the Treatment of Alzheimer's Disease: Primary Studies on Behavioral Test and Transcriptional Profiling

  2018cited by this paper
• Design of nonapeptide LVFFARKHH: A bifunctional agent against Cu2+‐mediated amyloid β‐protein aggregation and cytotoxicity

  2018cited by this paper
• Ac-LVFFARK-NH2 conjugation to β-cyclodextrin exhibits significantly enhanced performance on inhibiting amyloid β-protein fibrillogenesis and cytotoxicity.

  2018cited by this paper
• C-Terminal Fragment, Aβ39–42-Based Tetrapeptides Mitigates Amyloid-β Aggregation-Induced Toxicity

  2018cited by this paper
• Potential therapeutics of Alzheimer's diseases: New insights into the neuroprotective role of trehalose‐conjugated beta sheet breaker peptides

  2018cited by this paper
• Aromatic‐interaction‐mediated inhibition of β‐amyloid assembly structures and cytotoxicity

  2017cited by this paper
• PEGylated β-Sheet Breaker Peptides as Inhibitors of β-Amyloid Fibrillization.

  2017cited by this paper
• Retro-inverso peptide inhibitor nanoparticles as potent inhibitors of aggregation of the Alzheimer's Aβ peptide.

  2017cited by this paper
• Inhibition and Degradation of Amyloid Beta (Aβ40) Fibrillation by Designed Small Peptide: A Combined Spectroscopy, Microscopy, and Cell Toxicity Study.

  2017cited by this paper
• Study of a Bifunctional Aβ Aggregation Inhibitor with the Abilities of Antiamyloid-β and Copper Chelation.

  2016cited by this paper
• Natural Tripeptide-Based Inhibitor of Multifaceted Amyloid β Toxicity.

  2016cited by this paper
• C-Terminal Fragment, Aβ32-37, Analogues Protect Against Aβ Aggregation-Induced Toxicity.

  2016cited by this paper
• Ac‐LPFFD‐Th: A Trehalose‐Conjugated Peptidomimetic as a Strong Suppressor of Amyloid‐β Oligomer Formation and Cytotoxicity

  2016cited by this paper
• Design of LVFFARK and LVFFARK-functionalized nanoparticles for inhibiting amyloid β-protein fibrillation and cytotoxicity.

  2015cited by this paper
• Inhibition of β‐amyloid peptide self‐assembly and cytotoxicity by poly(LVFF‐co‐β‐amino ester)

  2015cited by this paper
• Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer´s Disease

  2015cited by this paper
• Rationally Designed Peptidomimetic Modulators of Aβ Toxicity in Alzheimer's Disease

  2015cited by this paper
• Covalent modifier-type aggregation inhibitor of amyloid-β based on a cyclo-KLVFF motif.

  2015cited by this paper
• Gold-nanoparticle-based multifunctional amyloid-β inhibitor against Alzheimer's disease.

  2015cited by this paper
• (R)‐α‐trifluoromethylalanine containing short peptide in the inhibition of amyloid peptide fibrillation

  2015cited by this paper
• Feasibility of β-Sheet Breaker Peptide-H102 Treatment for Alzheimer's Disease Based on β-Amyloid Hypothesis

  2014cited by this paper
• Reversal of aggregation using β-breaker dipeptide containing peptides: Application to Aβ(1-40) self-assembly and its inhibition.

  2014cited by this paper
• Rationally designed peptoids modulate aggregation of amyloid-beta 40.

  2014cited by this paper
• Study on the efficiency and interaction mechanism of a decapeptide inhibitor of β-amyloid aggregation.

  2014cited by this paper
• A Cyclic KLVFF‐Derived Peptide Aggregation Inhibitor Induces the Formation of Less‐Toxic Off‐Pathway Amyloid‐β Oligomers

  2014cited by this paper
• Rational design and identification of a non-peptidic aggregation inhibitor of amyloid-β based on a pharmacophore motif obtained from cyclo[-Lys-Leu-Val-Phe-Phe-].

  2014cited by this paper
• Self-assembled peptide-polyoxometalate hybrid nanospheres: two in one enhances targeted inhibition of amyloid β-peptide aggregation associated with Alzheimer's disease.

  2013cited by this paper
• Synthesis of d-amino acid peptides and their effect on beta-amyloid aggregation and toxicity in transgenic Caenorhabditis elegans

  2013cited by this paper
• A Novel Retro-Inverso Peptide Inhibitor Reduces Amyloid Deposition, Oxidation and Inflammation and Stimulates Neurogenesis in the APPswe/PS1ΔE9 Mouse Model of Alzheimer’s Disease

  2013cited by this paper
• Kinetic studies of inhibition of the amyloid beta (1-42) aggregation using a ferrocene-tagged β-sheet breaker peptide.

  2013cited by this paper
• Anti-Aggregating Effect of the Naturally Occurring Dipeptide Carnosine on Aβ1-42 Fibril Formation

  2013cited by this paper
• Ferrocene tripeptide Gly-Pro-Arg conjugates: synthesis and inhibitory effects on Alzheimer's Aβ(1-42) fibrillogenesis and Aβ-induced cytotoxicity in vitro.

  2013cited by this paper
• The multifactorial nature of Alzheimer's disease for developing potential therapeutics.

  2013cited by this paper
• Untangling amyloid-β, tau, and metals in Alzheimer's disease.

  2013cited by this paper
• Soluble Aβ oligomer production and toxicity

  2012cited by this paper
• Activation of α‐secretase cleavage

  2012cited by this paper
• Metallosupramolecular complex targeting an α/β discordant stretch of amyloid β peptide

  2012cited by this paper
• Engineered polymer nanoparticles containing hydrophobic dipeptide for inhibition of amyloid-β fibrillation.

  2012cited by this paper
• Inhibition of Amyloid Peptide Fragment Aβ25–35 Fibrillogenesis and Toxicity by N‐Terminal β‐Amino Acid‐Containing Esapeptides: Is Taurine Moiety Essential for In Vivo Effects?

  2012cited by this paper
• The N-methylated peptide SEN304 powerfully inhibits Aβ(1-42) toxicity by perturbing oligomer formation.

  2012cited by this paper
• C-terminal tetrapeptides inhibit Aβ42-induced neurotoxicity primarily through specific interaction at the N-terminus of Aβ42.

  2011cited by this paper
• Hydrophobic, aromatic, and electrostatic interactions play a central role in amyloid fibril formation and stability.

  2011cited by this paper
• Polyoxometalates as inhibitors of the aggregation of amyloid β peptides associated with Alzheimer's disease.

  2011cited by this paper
• Synthesis and evaluation of ferrocenoyl pentapeptide (Fc-KLVFF) as an inhibitor of Alzheimer's Aβ₁-₄₂ fibril formation in vitro.

  2011cited by this paper
• Development of retro-inverso peptides as anti-aggregation drugs for β-amyloid in Alzheimer's disease.

  2010cited by this paper
• Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for Alzheimer's disease.

  2010cited by this paper
• Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer's Disease transgenic mice.

  2010cited by this paper
• In vitro ADMET and physicochemical investigations of poly-N-methylated peptides designed to inhibit Abeta aggregation.

  2010cited by this paper
• Combining independent drug classes into superior, synergistically acting hybrid molecules.

  2010cited by this paper
• Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process

  2010cited by this paper
• Retro‐Enantio N‐Methylated Peptides as β‐Amyloid Aggregation Inhibitors

  2009cited by this paper
• Rationally designed dehydroalanine (ΔAla)‐containing peptides inhibit amyloid‐β (Aβ) peptide aggregation

  2009cited by this paper
• Design and biological activity of beta-sheet breaker peptide conjugates.

  2009cited by this paper
• Synthesis and biological evaluation of clicked curcumin and clicked KLVFFA conjugates as inhibitors of beta-amyloid fibril formation.

  2009cited by this paper
• A peptide hairpin inhibitor of amyloid beta-protein oligomerization and fibrillogenesis.

  2009cited by this paper
• Synthesis and activity of fibrillogenesis peptide inhibitors related to the 17-21 beta-amyloid sequence.

  2009cited by this paper
• Cognitive-performance recovery of Alzheimer's disease model mice by modulation of early soluble amyloidal assemblies.

  2009cited by this paper
• Design and synthesis of new trehalose‐conjugated pentapeptides as inhibitors of Aβ(1–42) fibrillogenesis and toxicity

  2009cited by this paper
• Hybrid peptides attenuate cytotoxicity of beta-amyloid by inhibiting its oligomerization: implication from solvent effects.

  2009cited by this paper
• Poly-N-methylated amyloid beta-peptide (Abeta) C-terminal fragments reduce Abeta toxicity in vitro and in Drosophila melanogaster.

  2009cited by this paper
• Design and characterization of a membrane permeable N-methyl amino acid-containing peptide that inhibits Aβ1–40 fibrillogenesis

  2008cited by this paper
• Reduction of Alzheimer’s Disease Amyloid Plaque Load in Transgenic Mice by D3, a D‐Enantiomeric Peptide Identified by Mirror Image Phage Display

  2008cited by this paper
• Designing peptide inhibitors for oligomerization and toxicity of Alzheimer's beta-amyloid peptide.

  2008cited by this paper
• C-terminal peptides coassemble into Aβ42 oligomers and protect neurons against Aβ42-induced neurotoxicity

  2008cited by this paper
• Branched KLVFF Tetramers Strongly Potentiate Inhibition of β‐Amyloid Aggregation

  2007cited by this paper
• Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles.

  2006cited by this paper
• N-Methylated Peptide Inhibitors of β-Amyloid Aggregation and Toxicity. Optimization of the Inhibitor Structure†

  2006cited by this paper
• Protein misfolding, functional amyloid, and human disease.

  2006cited by this paper
• Stoichiometric Inhibition of Amyloid β-Protein Aggregation with Peptides Containing Alternating α,α-Disubstituted Amino Acids

  2006cited by this paper
• Design of peptidyl compounds that affect beta-amyloid aggregation: importance of surface tension and context.

  2005cited by this paper
• Pentapeptides derived from Abeta 1-42 protect neurons from the modulatory effect of Abeta fibrils--an in vitro and in vivo electrophysiological study.

  2005cited by this paper
• Eight-residue Aβ peptides inhibit the aggregation and enzymatic activity of Aβ42

  2004cited by this paper
• Inhibition of beta-amyloid toxicity by short peptides containing N-methyl amino acids.

  2004cited by this paper
• Beta-amyloid-derived pentapeptide RIIGLa inhibits Abeta(1-42) aggregation and toxicity.

  2004cited by this paper
• In vitro model of neurotoxicity of Aβ 1–42 and neuroprotection by a pentapeptide: irreversible events during the first hour

  2004cited by this paper
• β-sheet breaker peptide prevents Aβ-induced spatial memory impairments with partial reduction of amyloid deposits

  2004cited by this paper
• Probing the role of backbone hydrogen bonding in beta-amyloid fibrils with inhibitor peptides containing ester bonds at alternate positions.

  2003cited by this paper
• Selection of D‐Amino‐Acid Peptides That Bind to Alzheimer's Disease Amyloid Peptide Aβ1–42 by Mirror Image Phage Display

  2003cited by this paper
• Multiple-Peptide Conjugates for Binding β-Amyloid Plaques of Alzheimer's Disease

  2003cited by this paper
• The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide.

  2003cited by this paper
• Reduction of amyloid load and cerebral damage in transgenic mouse model of Alzheimer's disease by treatment with a β‐sheet breaker peptide

  2002cited by this paper
• Therapeutic strategies for human amyloid diseases

  2002cited by this paper
• Beta‐sheet breaker strategy for the treatment of Alzheimer's disease

  2002cited by this paper
• Inhibition of toxicity and protofibril formation in the amyloid-β peptide β(25–35) using N-Methylated derivatives

  2002cited by this paper
• Pentapeptide amides interfere with the aggregation of beta-amyloid peptide of Alzheimer's disease.

  2002cited by this paper
• Peptide inhibitors of beta amyloid aggregation.

  2002cited by this paper
• Inhibitors of fibril formation and cytotoxicity of β-amyloid peptide composed of KLVFF recognition element and flexible hydrophilic disrupting element

  2002cited by this paper
• Inhibition of beta-amyloid(40) fibrillogenesis and disassembly of beta-amyloid(40) fibrils by short beta-amyloid congeners containing N-methyl amino acids at alternate residues.

  2001cited by this paper
• Characterization of cholyl-leu-val-phe-phe-ala-OH as an inhibitor of amyloid beta-peptide polymerization

  2001cited by this paper

• Sustainable Therapeutic Strategies for Controlling Amyloid Aggregation Process

  2026cites this paper
• Approaches for developing peptide- and metal complexes- or chelators-based leads for anti-amyloid drugs

  2025cites this paper
• Molecular Mechanism of Beta-Amyloid Aggregation Inhibition by KLVFF

  2025cites this paper
• Discovery of New Pentapeptide Inhibitors Against Amyloid-β Aggregation Using Word2Vec and Molecular Simulation.

  2025cites this paper
• NMR studies of amyloid interactions.

  2024cites this paper
• Distinguishing features of depression in dementia from primary psychiatric disease

  2024cites this paper
• Rapid Discovery of Aβ42 Fibril Disintegrators from Ganoderma lucidum via Ligand Fishing and Their Neuroprotective Effects on Alzheimer's Disease.

  2024cites this paper
• Current strategies of detecting Aβ species and inhibiting Aβ aggregation: Status and prospects

  2023cites this paper
• The Strategies of Development of New Non-Toxic Inhibitors of Amyloid Formation

  2023cites this paper
• Sodium Oligomannate Electrostatically Binds to Aβ and Blocks Its Aggregation.

  2023cites this paper
• Cyclic β-hairpin peptide loaded PLGA nanoparticles: a potential anti-amyloid therapeutic

  2023cites this paper
• Cyclic di-peptide in situ inhibited protein-aggregation.

  2023cites this paper
• Targeted protein degradation: a new paradigm in medicinal chemistry.

  2022cites this paper
• Versatile tools of synthetic biology applied to drug discovery and production.

  2022cites this paper
• Glucosyl Platinum(II) Complexes Inhibit Aggregation of the C-Terminal Region of the Aβ Peptide

  2022cites this paper